Immune mechanisms of psoriasis. New strategies of biotherapy


Psoriasis is a chronic skin disease - according to numerous studies, about 2% of the population suffer from it. Psoriasis degrades the life quality, and such concomitant pathologies as metabolic disorders, cardiovascular diseases and depression shorten the life expectancy of psoriasis patients. Substantial progress has been achieved today in understanding the mechanisms of the disease, searching for new treatment techniques and standardizing the disease severity
According to the recent studies, psoriasis belongs to immune-dependent diseases with genetic predisposition to its development. Dendritic cells and T lymphocytes play an important part in psoriasis development. Their interaction launches a number of mechanisms ultimately leading to the inflammatory process development and formation of psoriatic skin affections. Such cytokines as IL-12, IL-23, IFN-y and TNF-a secreted by immunocompetent cells serve as mediators during such processes. An advanced therapeutic approach to the treatment of psoriasis means creating pathogenetically important cytokine specific monoclonal antibodies and placing them into the body Today there are drugs successfully blocking the development of psoriatic skin affections by means of specific binding of IL-12, IL-23 and TNF-a cytokines. Drugs called ustekinumab and ABT-874 confirmed their therapeutic activity with regard to psoriasis at Phases 2 and 3 of clinical trials. In the course of further trials, ustekinumab also demonstrated a safety profile comparable to that of placebo.


  1. Adalimumab SPC. Available from: Accessed 13 Nov 2008.
  2. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71(1):1-8.
  3. Aggarwal S, Ghilardi N, Xie M-H, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910-4.
  4. Akay A, Pekcanlar A, Bozdag KE, et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. JEADV. 2002;16:347-52.
  5. Albanesi C, De Pita O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol. 2007;25(6):581-8.
  6. Alefacept SPC. Available from Accessed 27 Jan 2009
  7. Becker K.G., Simon R.M., Bailey-Wilson J.E., et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A. 1998;95:9979-84.
  8. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA. 2006;295:2275-85.
  9. Brimhall A.K., King L.N., Licclardone J.C., et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:274-85.
  10. Brok H.P., van Meurs M., Blezer E. et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol. 2002 Dec 1;169(11):6554-63.
  11. Capon F., Di Meglio P., Szaub J., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its li-gand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122(2):201-6.
  12. Cargill M., Schrodi S.J., Chang M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273-90.
  13. Carrascosa J.M., Pujol R., Daudén E., et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20(7):840-5.
  14. Chan J.R., Blumenschein W., Murphy E., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577-87.
  15. Chren M.M., Lasek R.J., Flocke S.A., Zyzanski S.J.. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-40.
  16. Christophers E., Griffiths C.E., Gaitanis G., et al. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol. 2006;20:921-5.
  17. Cordoba-Rodriguez R., Frucht D.M. IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin Biol Ther. 2003;3(5):715-23.
  18. Costa C., Incio J., Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 2007;10(3):149-66.
  19. Curtsinger J.M., Schmidt C.S., Mondino A., et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999;162(6):3256-62.
  20. Data on file: C0743T09 Clinical Study, Centocor Inc.
  21. Davidsson S., Blomqvist K., Molin L., et al. Lifestyle of Nordic people with psoriasis. In J Dermatol. 2005;44:378-83.
  22. Devrimci-Ozguven H., Kundakci T.N., Kumbasar H., et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000; 14(4):267-71.
  23. Dubertret L., Mrowietz U., Ranki A., et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155:729-36.
  24. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314:1461-3.
  25. Efalizumab SPC. Available from: Accessed 13 Nov 2008.
  26. Etanercept SPC. Available from: Accessed 13 Nov 2008.
  27. Eyre R.W., Krueger G.G.. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and 'reverse' Koebner reactions. Br J Dermatol. 1982;106(2):153-9.
  28. Farber E.M., Nall L. Psoriasis and alcoholism. Cutis. 1994; 53:21-7.
  29. Farber E.M., Nall M.L., Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;109(2):207-11.
  30. Food and Drug Administration. FDA approves updated drug labelling for psoriasis drug Raptive: Safety concerns drove labelling changes. Available from. Accessed 27 January 2009.
  31. Feldman S.R., Krueger G.G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:ii65-ii68.
  32. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)%a simple practical measure for routine clinical use. Clin Exp Derma-tol. 1994; 19:210-6.
  33. Fitch E., Harper E., Skorcheva I. et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007 Dec;9(6):461-7.
  34. Fortes C., Mastroeni S., Leffondre K., et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580-4.
  35. Fortune D.G., Main C.J., O'Sullivan T.M., et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997; 137(5):755-60.
  36. Gately M.K., Renzetti L.M., Magram J., et al. The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521.
  37. Gelfand J.M., Weinstein R., Porter S.B., et al. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol. 2005;141:1537-41.
  38. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA .2006;296:1735-41.
  39. Gelfand J.M., Troxel A.B., Lewis J.D., et al. The risk of mortality in patients with psoriasis. Arch Dermatol .2007;143:1493-99.
  40. Gladman D.D., Antoni C., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl II):ii14-ii17.
  41. Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004; 51(4):534-42.
  42. Griffiths C., Strober B., van de Kerkhof P.C.M., et al. A Phase 3, Multicenter, Randomized Study Comparing Ustekinumab and Etan-ercept for the Treatment of Moderate to Severe Plaque Psoriasis. Poster presented at EADV, Sep 17-21 2008, Paris. Poster FP1336.
  43. Griffiths C.E.M., Barker J.N.W.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-71.
  44. Gudjonsson J.E., Thorarinsson A.M., Sigurgeirsson B., et al. Strepto-coccal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol. 2003;149(3):530-4.
  45. Gudjonsson J.E., Elder J.T. Psoriasis: epidemiology. Clin Dermatol. 2007; 25(6):535-46.
  46. Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846-50.
  47. EMEA Press release. 19 Feb, 2009. Available at: http://www.emea. Accessed 6 Mar 2009.
  48. Henseler T., Cristophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985; 13:450-6.
  49. Henseler T., Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32: 982-6.
  50. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527-34.
  51. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658-65.
  52. Hong K., Chu A., Ludviksson B.R., et al. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol. 1999;162(12):7480-91.
  53. Infliximab S.P.C. Available from: Accessed on 13 Nov 2008.
  54. Jariwala S.P. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007 Oct;299(8):359-66.
  55. Kauffman C.L., Aria N., Toichi E., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037-44.
  56. Kimball A.B., Jacobson C., Weiss S., et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6(6):383-92.
  57. Kimball A.B., Gordon K.B., Langley R.G., et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomised, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200-7.
  58. Kindt T.J., et al. Immunology. 6th ed. New York: WH Freeman; 2007.
  59. Krueger G.G., Feldman S.R., Camisa C., et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-5.
  60. Krueger G., Koo J., Lebwohl M., et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-4.
  61. Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-9.
  62. Langley R., Lebwohl M., Krueger G.G., et al. CNTO 1275 significantly improves quality of life in patients with psoriasis: Results from PHOENIX 2 (a phase III, randomized, controlled trial. Oral presentation. 21st World Congress of Dermatology, October 1-5, 2007, Buenos Aires, Argentina.
  63. Lee C.S., Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother. 2005;6(10):1725-34.
  64. Lee E., Trepicchio W.L., Oestreicher J.L., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-30.
  65. Leonardi C., et al. Poster presented at AAD, Feb 1-5 2008, San Antonio, Texas.
  66. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74.
  67. Liu Y., Krueger J.G., Bowcock A.M. Psoriasis: genetic associations and immune system changes. Genes Immun. 2007;8(1):1-12.
  68. Lomholt G. Psoriasis: Prevalence, spontaneous course and genetics. A census study of skin diseases on the Faroe Islands. Ph.D Thesis. Copenhagen, 1963.
  69. Lomholt G. Prevalence of skin diseases in a population: A census study from the Faroe Islands. Dan Med Bull. 1964;11(1):1-7.
  70. Lowes M.A., Lew W., Krueger J.G. Current concepts in the immu-nopathogenesis of psoriasis. Dermatol Clin. 2004;22(4):349-69, vii.
  71. Lowes M.A., Kikuchi T., Fuentes-Duculan J., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-11.
  72. Menter A., Griffiths C.E. Current and future management of psoriasis. Lancet. 2007;370(9583):272-84.
  73. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-15.
  74. Nast A., Kopp I.B., Augustin M. et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2007 Jul;5 Suppl 3:1-119
  75. National Psoriasis Foundation. About psoriasis: statistics. Accessed at on 15th August 2008.
  76. Nickoloff B.J., Nestle F.O. Recent insights into the immunopatho-genesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12):1664-75.
  77. Nijsten T., Margolis D.J., Feldman S.R., et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52(3 Pt 1):434-44.
  78. Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304-12.
  79. Papp K.A. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298 (1):7-15.
  80. Papp K., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84.
  81. Petty A.A., Balkrishnan R., Rapp S.R., et al. Patients with palmoplan-tar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications fro clinical practice. J Am Acad Dermatol. 2003;49:271-5.
  82. Piskin G., Sylva-Steenland R.M., Bos J.D., et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908-15.
  83. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41(3 Pt 1):401-7.
  84. Ramsay B., O'Reagen M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. 1988;118(2):195-201.
  85. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-74.
  86. Richards H.L., Ray D.W., Kirby B., et al. Response of the hypotha-lamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol. 2005;153(6):1114-20.
  87. Schlaak J.F., Buslau M., Jochum W., et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102(2):145-9.
  88. Schoffski O., Augustin M., Prinz J., et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5(3):209-18.
  89. Shear N.H. Fulfilling an unmet need in psoriasis. Do biologicals hold the key to improved tolerability? Drug Safety. 2006;29(11):49-66.
  90. Setty A.R., Curhan G., Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med. 2007;120(11):953-9.
  91. Smith C.H., Anstey A.V., Barker J.N.W.N,. et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 Br J Dermatol. 2005;153:486-97.
  92. Stern R.S., Nijsten T., Feldman S.R., et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
  93. Telfer N.R., Chalmers R.J., Whale K., et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39-42.
  94. Tiilikainen A., Lassus A., Karvonen J., et al. Psoriasis and HLA-Cw6. Br J Dermatol. 1980;102(2):179-84.
  95. Toichi E., Torres G., McCormick T.S., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/ IL-23 in psoriasis. J Immunol. 2006;177(7):4917-26.
  96. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813-20.
  97. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133-46.
  98. Tsankov N., Angelova I., Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1(3):159-65.
  99. Tsunemi Y., Saeki H., Nakamura K., et al. Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002;30(2):161-6.
  100. Tubach F., Salmon D., Ravaud P., et al. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Results of the French 3-year prospective ratio observatory. Presentation at EULAR, Jun 11-14 2008, Paris.
  101. Uyemura K., Yamamura M., Fivenson D.F., et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701-5.
  102. Vardy D., Besser A., Amir M., et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002;147(4):736-42.
  103. Weiss S.C., Kimball A.B., Liewehr D.J., et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512-18.
  104. Wilson N.J., Boniface K., Chan J.R, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-7.
  105. Witowski J., Pawlaczyk K., Breborowicz A., et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol. 2000;165(10):5814-21.
  106. Wolf R., Wolf D., Ruocco V. Alcohol intake and psoriasis. Clin Dermatol. 1999;17:423-30.
  107. Yawalkar N., Karlen S., Hunger R., et al. Expression of inter-leukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053-7.
  108. Yip S.Y. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol. 1984;10:965-8.
  109. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648-51.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies